{"filing":{"accession_number":"0001193125-26-313400","cik":"0001750149","ticker":"IKT","company_name":"Inhibikase Therapeutics, Inc.","form":"8-K","filing_date":"2026-07-23","report_date":null,"primary_document":"d121491d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1750149/000119312526313400/d121491d8k.htm"},"events":[{"id":19879,"run_id":17891,"accession_number":"0001193125-26-313400","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"The disclosure announces FDA Orphan Drug Designation (ODD) for IKT-001 in PAH treatment. This is a regulatory milestone that provides development incentives (tax credits, fee exemptions, seven-year market exclusivity) and reflects progress in the company's lead product development. While not a specific named event type, this is clearly an operational/regulatory milestone material to a clinical-stage biotech company's prospects, warranting classification as operational_other rather than other_material since the domain (operational/regulatory) is clear.","company_name":"Inhibikase Therapeutics, Inc.","ticker":"IKT","filing_date":"2026-07-23","form":"8-K","submitted_at":null,"items":[{"id":19095,"accession_number":"0001193125-26-313400","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces FDA Orphan Drug Designation (ODD) for IKT-001 in PAH treatment. This is a regulatory milestone that provides development incentives (tax credits, fee exemptions, seven-year market exclusivity) and reflects progress in the company's lead product development. While not a specific named event type, this is clearly an operational/regulatory milestone material to a clinical-stage biotech company's prospects, warranting classification as operational_other rather than other_material since the domain (operational/regulatory) is clear.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-23T12:33:49.733830+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":19095,"accession_number":"0001193125-26-313400","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces FDA Orphan Drug Designation (ODD) for IKT-001 in PAH treatment. This is a regulatory milestone that provides development incentives (tax credits, fee exemptions, seven-year market exclusivity) and reflects progress in the company's lead product development. While not a specific named event type, this is clearly an operational/regulatory milestone material to a clinical-stage biotech company's prospects, warranting classification as operational_other rather than other_material since the domain (operational/regulatory) is clear.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-23T12:33:49.733830+00:00","company_name":"Inhibikase Therapeutics, Inc.","ticker":"IKT","filing_date":"2026-07-23"}]}